hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 15:20:54 - browse：529

Dallas Mavericks owner Mark Cuban reacts during a timeout in the game against the Golden State Warriors at American Airlines Center on March 22, 2023 in Dallas, Texas. – opinion coverage from STAT — Tim Heitman/Getty Images

Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his direct-to-consumer venture, Cost Plus Drugs. The company sells generic prescription drugs and boasts more than 2 million members. As a family medicine specialist who has firsthand experience with American households’ dissatisfaction with the state of the nation’s prescription drug marketplace, I believe the enthusiasm for Cost Plus Drugs reveals an appetite for alternatives to the status quo in the pharmaceutical industry.

Cuban claims the reason behind the success of Cost Plus Drugs is the company’s decision to bypass pharmaceutical benefit managers — the negotiating agents insurance companies hire to negotiate big pharma’s prices down. But that might not be the case. Instead, its success appears to lie in its choice to collaborate with affordable generic drug manufacturers rather than the major pharmaceutical companies.

Last year, the Department of Health and Human Services found that between July 2021 and July 2022, major pharma companies raised the list price on more than 1,200 drugs by an average of 31 percent. That’s 23 percent more than the country’s overall inflation rate during the same period. Meanwhile, generic drug companies saved the U.S. roughly $2.6 trillion from 2012 to 2021, according to the Association for Accessible Medicines, a trade group representing generic drug manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA greenlights medical device to combat bladder issues

focus

WSS

Meadows told special counsel he could not recall Trump ever declassifying Mar

Study suggests Covid rebound is far more common with Paxlovid than without

Vivek Ramaswamy made waves in the debate, much as in biotech

How the first Native Hawaiian psychiatrist helped diversify medicine

People can get long Covid without testing positive for virus: Study

After decades in use, heart stents finally beat placebo

focus

hotspot

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

How the drug

Medical leaders decry Supreme Court decision on affirmative action

Former Pear Therapeutics executives start new VC firm

How to save PrEP access — and even expand it

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

The high cost of giving birth even with insurance

White House drug czar issues call for 'recovery

Walensky prepares to leave CDC — and Congress — behind

National associations that represent hospice owe an apology

explore

Healthy food access boosts outcomes in two studies

Type 2 diabetes prevention programs work at large scale: study

Health officials lay out plans to cope with respiratory virus season

Medical school prerequisites are outdated

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

How the drug

entertainment

leisure time

focus

Wikipedia